Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

We maintain our long-term Neutral recommendation on BioScrip Inc. (BIOS - Analyst Report). Although the company has several positive catalysts to drive growth over the long haul, looming concerns keep us on the sidelines for this pharmacy benefit manager and infusion service provider. 
 
Why the Reiteration?
 
BioScrip’s results in the most recent quarter surpassed the Zacks Consensus Estimate. While revenues shot up 27.3% year over year, adjusted earnings per share was in line with the year-ago results.
 
Following the divestment of pharmacy services business to Walgreens (WAG - Analyst Report), BioScrip increased its focus on its Infusion franchise. This is reflected in the recent acquisition of HomeChoice which will significantly boost revenue in the future. The buyout is expected to be accretive to BioScrip’s annual top-line by $70 million. However, we are apprehensive about integration risks.  
 
While the company enjoys strong presence and competitive advantage in the Infusion and Home Health industry, the competitive landscape with larger players and deeper pockets remains unyielding. The competitive pressure also led to aggressive price wars in the last quarter. Consequently, margins remained under pressure. 
 
The decline in Home Health reimbursement rates from certain government players also negatively impacted the company by creating a challenging operating environment. We note that BioScrip derived 33% of its revenues directly from Medicare, Medicaid or other government-sponsored healthcare programs in the third quarter. Reimbursement cuts are therefore a looming concern.
 
Based on these factors, estimates for 2013 for BioScrip have remained stagnant over the last 30 days. Accordingly, the stock carries a Zacks Rank #3 (Hold). 
 
Other Stocks to Consider 
 
We continue to monitor the future developments at BioScrip which might affect its financial results. Meanwhile, other medical stocks such as Given Imaging , ResMed (RMD - Analyst Report) and Medical Action (MDCI), carrying a Zacks Rank #1 (Strong Buy) are expected to do well in the near term. 
We maintain our long-term Neutral recommendation on BioScrip Inc. (BIOS - Analyst Report). Although the company has several positive catalysts to drive growth over the long haul, looming concerns keep us on the sidelines for this pharmacy benefit manager and infusion service provider. 
 
Why the Reiteration?
 
BioScrip’s results in the most recent quarter surpassed the Zacks Consensus Estimate. While revenues shot up 27.3% year over year, adjusted earnings per share was in line with the year-ago results.
 
Following the divestment of pharmacy services business to Walgreens (WAG - Analyst Report), BioScrip increased its focus on its Infusion franchise. This is reflected in the recent acquisition of HomeChoice which will significantly boost revenue in the future. The buyout is expected to be accretive to BioScrip’s annual top-line by $70 million. However, we are apprehensive about integration risks.  
 
While the company enjoys strong presence and competitive advantage in the Infusion and Home Health industry, the competitive landscape with larger players and deeper pockets remains unyielding. The competitive pressure also led to aggressive price wars in the last quarter. Consequently, margins remained under pressure. 
 
The decline in Home Health reimbursement rates from certain government players also negatively impacted the company by creating a challenging operating environment. We note that BioScrip derived 33% of its revenues directly from Medicare, Medicaid or other government-sponsored healthcare programs in the third quarter. Reimbursement cuts are therefore a looming concern.
 
Based on these factors, estimates for 2013 for BioScrip have remained stagnant over the last 30 days. Accordingly, the stock carries a Zacks Rank #3 (Hold). 
 
Other Stocks to Consider 
 
We continue to monitor the future developments at BioScrip which might affect its financial results. Meanwhile, other medical stocks such as Given Imaging and ResMed (RMD - Analyst Report), carrying a Zacks Rank #1 (Strong Buy) are expected to do well in the near term.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%